

EXHIBIT 6

IN THE
**United States Patent and
Trademark Office**
Before the Board of Patent Appeals and Interferences

Interference No. 102,096
Interference No. 102,097
and
Interference No. 102,334

FRITSCH

v.

LIN

Examiner-in-Chief Marc L. Caroff

FRITSCH EXHIBITS
VOLUME XVIII
(Exhibits FX 398 cont. to FX 417)

KURT E. RICHTER
MORGAN & FINNEGAN
345 Park Avenue
New York, New York 10154
(212) 758-4800
Attorneys for Fritsch

Of Counsel:
EUGENE MOROZ
WILLIAM S. FEILER
MICHAEL P. DOUGHERTY
WILLIAM KROVATIN

AM 17 049165
CONFIDENTIAL
SUBJECT TO PROTECTIVE ORDER

Trial Exhibit 207
97-10814-WGY

Trial Exhibit ATD
97-10814-WGY

r-HuEPO Product License Application
Table of Contents

Amgen, Inc.
1900 Oak Terrace Lane
Thousand Oaks, CA 91320

TABLE OF CONTENTS

<u>Item</u>	<u>Description</u>	<u>Volume/Page</u>
OVERALL SUMMARY		
A.	Annotated Package Insert.....	1/Summary 0001
B.	Product Description, Scientific Rationale, Intended Use, and Potential Clinical Benefits.....	1/Summary 0013
C.	Summary of Product Manufacture.....	1/Summary 0015
D.	Summary of Non-Clinical Pharmacology.....	1/Summary 0021
E.	Summary of Toxicology Studies.....	1/Summary 0031
F.	Summary of Clinical Experience	
	1. Integrated Summary of Efficacy.....	1/Summary 0055
	2. Integrated Summary of Safety.....	1/Summary 0078
G.	Benefit/Risk Evaluation.....	1/Summary 0113
1.	GENERAL INFORMATION.....	1/0001
A.	Product Identification.....	1/0001
B.	Manufacturer's Name, Address, Zip Code and Phone Number.....	1/0003
C.	Complete Addresses of Locations of Product Manufacturer(s).....	1/0004
D.	Facility Map.....	1/0006
2.	DEVELOPMENT AND CHARACTERIZATION OF r-HuEPO PRODUCTION SYSTEM.....	1/0007
1.	Molecular Biology of the Erythropoietin Gene.....	1/0011
	1. Summary.....	1/0011
	2. Flow Chart.....	1/0013
	3. Cloning of the Human Erythropoietin Gene.....	1/0014

05027129

Amgen Confidential Business Information,
Subject To ITC Protective Order

DEFENDANT'S
EXHIBIT
 AM 17 048934
 CONFIDENTIAL
 SUBJECT TO PROTECTIVE ORDER

A 27110

FRITSCH V. LIN
INTER. 102,096, 102,097 & 102,334
FRITSCH EVID.



EX. 388

EX-101

r-HuEPO Product License Application
 Table of Contents

Amgen, Inc.
 1900 Oak Terrace Lane
 Thousand Oaks, CA 91320

<u>Item</u>	<u>Description</u>	<u>Volume/Page</u>
4.	Transient Expression of the Cloned Human Erythropoietin Gene.....	1/0018
5.	Characterization of the Human Genomic Erythropoietin Clone.....	1/0021
6.	Genome Organization of the Human Erythropoietin Gene.....	1/0024
7.	Sequencing the Human Erythropoietin Gene and the Analysis of the Sequence.....	1/0026
8.	Sequencing Strategy.....	1/0030
9.	Expression of r-HuEPO.....	1/0032
B.	Construction and Genetic Characterization of Production Cell Line.....	1/0034
1.	Summary.....	1/0034
2.	Flow Chart.....	1/0035
3.	Construction and Genetic Characterization of Production Cell Line.....	1/0036
C.	Master Working Cell Bank.....	1/0064
1.	Production.....	1/0064
2.	Characterization.....	1/0074
3.	Identity Testing.....	1/0110
4.	Storage and Maintenance of Master Working Cell Bank...1/0116	
D.	Figures	1/0118
E.	References.....	1/0201
3.	PREPARATION OF PURIFIED BULK PRODUCT.....	2/0208
A.	Introduction.....	2/0209
B.	Flow Chart.....	2/0211

05027130

Amgen Confidential Business Information
 Subject To ITC Protective Order

A 27111

AM 17 048935
 CONFIDENTIAL
 SUBJECT TO PROTECTIVE ORDER

r-HuEPO Product License Application
Table of Contents

Amgen, Inc.
1900 Oak Terrace Lane
Thousand Oaks, CA 91320

<u>Item</u>	<u>Description</u>	<u>Volume/Page</u>
C.	r-HuEPO Production/Cell Culture.....	2/0212
1.	Overview.....	2/0212
2.	Cell Culture Process Description.....	2/0216
3.	Raw Materials and Equipment.....	2/0232
4.	In-Process Controls and Specifications.....	2/0247
5.	Validation Overview.....	2/0256
D.	Protein Purification Operations.....	2/0258
1.	Overview/Flow Chart.....	2/0258
2.	Process Description.....	2/0261
3.	Raw Materials and Equipment.....	2/0278
4.	In-Process Controls and Specifications.....	2/0291
5.	Validation Overview.....	2/0298
E.	Figures	2/0325
F.	References.....	2/0350
4.	PREPARATION OF FORMULATED BULK PRODUCT.....	2/0351
A.	Summary	2/0352
B.	Flow Chart.....	2/0353
C.	Process Description.....	2/0354
1.	Formulation.....	2/0354
2.	Cleaning and Sterilization.....	2/0358
D.	Equipment, Raw Materials and Solutions.....	2/0359
E.	In-Process Controls and Specifications.....	2/0362
F.	Validation Overview.....	2/0363

CONFIDENTIAL

Amgen Confidential Business Information,
Subject To ITC Protective Order

A 27112

AM 17 048936
CONFIDENTIAL
SUBJECT TO PROTECTIVE ORDER

r-HuEPO Product License Application
Table of Contents

Amgen, Inc.
1900 Oak Terrace Lane
Thousand Oaks, CA 91320

<u>Item</u>	<u>Description</u>	<u>Volume/Page</u>
5.	STORAGE AND SHIPMENT OF BULK PRODUCT.....	2/0364
	A. Summary	2/0364
	B. Description (Containers/Conditions/Labeling).....	2/0365
	C. Product Stability Under Storage/shipment2/ Conditions.....	2/0367
	D. Figures	2/0369
6.	PREPARATION OF FINAL PRODUCT.....	2/0384
	A. Quantitative/Qualitative Compositions; Dosage Forms.....	2/0385
	B. Preservatives/Diluents.....	2/0388
	C. Process Description.....	2/0389
	D. Equipment and Raw Materials.....	2/0391
	E. Preparation/Processing of Containers/Closures.....	2/0394
	F. In-Process Controls and Specifications.....	2/0395
	G. Reprocessing/Rework Procedures.....	2/0396
	1. Sterility.....	2/0397
	2. Particulates.....	2/0397
	3. Strength.....	2/0398
	4. Endotoxins.....	2/0399
	5. Protein Contamination.....	2/0401
	6. DNA Contamination.....	2/0402
	7. Excipient (buffer) Concentration.....	2/0403
	8. pH	2/0404
	H. Validation Summary.....	2/0405

05027132

Amgen Confidential Business Information,
Subject To ITC Protective Order

A 27113

AM 17 048937
CONFIDENTIAL
SUBJECT TO PROTECTIVE ORDER

r-HuEPO Product License Application
Table of Contents

Amgen, Inc.
1900 Oak Terrace Lane
Thousand Oaks, CA 91320

<u>Item</u>	<u>Description</u>	<u>Volume/Page</u>
I.	Return and Storage of Final Product.....	2/0406
J.	Figures	2/0407
7.	LOT NUMBERING OF IN-PROCESS AND FINAL PRODUCT.....	2/0415
A.	Summary	2/0415
B.	Flow Chart.....	2/0417
C.	Concentrated, Diafiltered Medium (Culture Number).....	2/0418
D.	Purified Bulk (Lot Number).....	2/0419
E.	Formulated Bulk.....	2/0420
F.	Final Dosage Form (Final Lot Number).....	2/0421
B.	IN-PROCESS AND FINAL PRODUCT TESTING.....	2/0423
A.	Summary	2/0424
B.	Outline of Tests and Acceptance Criteria.....	2/0426
1.	Cell Inoculum for Production of r-HuEPO.....	2/0426
2.	Purified Bulk r-HuEPO.....	2/0427
3.	Formulated Bulk r-HuEPO.....	2/0432
4.	Sterile Formulated Bulk r-HuEPO.....	2/0433
5.	Final Product r-HuEPO.....	2/0434
C.	Descriptions of In-Process and Final Product Testing Methods.....	2/0435
1.	Assays for Product Identity and Characterization.....	2/0436
2.	Assays for Product Purity.....	2/0446
3.	Assays for Determination of Product Potency.....	2/0455
4.	Other Tests.....	2/0459

05027133

Amgen Confidential Business Information,
Subject To ITC Protective Order

A 27114

AM 17 048938
CONFIDENTIAL
SUBJECT TO PROTECTIVE ORDER

r-HuEPO Product License Application
Table of Contents

Amgen, Inc.
1900 Oak Terrace Lane
Thousand Oaks, CA 91320

<u>Item</u>	<u>Description</u>	<u>Volume/Page</u>
D.	Validation Summaries.....	3/0466
E.	r-HuEPO Reference Standards.....	3/0737
	1. Protein Chemistry Standard.....	3/0737
	2. Potency Standard.....	3/0739
F.	Figures.....	3/0743
G.	References.....	3/0759
9.	FINAL PRODUCT CHARACTERIZATION.....	4/0760
A.	Summary.....	4/0762
B.	Physical Properties of Erythropoietin.....	4/0764
	1. Summary.....	4/0764
	2. Primary Amino Acid Sequence.....	4/0766
	3. Carboxy-Terminal Analysis.....	4/0770
	4. Amino Acid Composition.....	4/0776
	5. Hydrodynamic Studies of r-HuEPO.....	4/0777
	6. Circular Dichroic Spectra of Erythropoietin.....	4/0781
	7. Fluorescence and Phosphorescence Spectroscopy of Erythropoietin.....	4/0783
	8. Determination of Dry Weight of r-HuEPO.....	4/0786
	9. Analytical HPLC Gel Filtration.....	4/0787
	10. Isoelectric Focusing of r-HuEPO.....	4/0788
	11. Comparison of r-HuEPO to u-HuEPO.....	4/0789
C.	Carbohydrate Structure of r-HuEPO and u-HuEPO.....	4/0791

05027134

Amgen Confidential Business Information.
Subject To ITC Protective Order

A 27115

AM 17 048939
CONFIDENTIAL
SUBJECT TO PROTECTIVE ORDER

r-HuEPO Product License Application
Table of Contents

Amgen, Inc.
1900 Oak Terrace Lane
Thousand Oaks, CA 91320

<u>Item</u>	<u>Description</u>	<u>Volume /Page</u>
D.	Biological and Immunological Properties of Erythropoietin.....	4/0801
1.	Erythropoietin Bioassays.....	4/0802
2.	Immunological Assays of Erythropoietin.....	4/0816
3.	Effect of r-HuEPO on Other Hematopoietic Progenitor Cells.....	4/0825
4.	Comparison of r-HuEPO to u-HuEPO.....	4/0841
E.	Process Characterization.....	4/0843
1.	Summary.....	4/0843
2.	Cell Culture Process.....	4/0844
3.	Protein Purification Process.....	4/0850
F.	Figures.....	4/0859
G.	References.....	4/0982
10.	STABILITY AND EXPIRATION DATING.....	5/0987
A.	Summary.....	5/0988
B.	Real-Time Stability Data and Discussion.....	5/0990
1.	Methods Used to Determine Stability of Final Product r-HuEPO and Excipients.....	5/0990
2.	Study Design.....	5/0996
3.	Summary of r-HuEPO Stability Program.....	5/1000
4.	Results and Discussion.....	5/1001
5.	Additional Experimentation.....	5/1009
C.	Accelerated Stability Data.....	5/1012
D.	Product Expiration Dating.....	5/1016
1.	Product Expiry.....	5/1016

05027135

Amgen Confidential Business Information,
Subject To ITC Protective Order

A 27116

AM 17 048940
CONFIDENTIAL
SUBJECT TO PROTECTIVE ORDER

r-HuEPO Product License Application
Table of Contents

Amgen, Inc.
1900 Oak Terrace Lane
Thousand Oaks, CA 91320

<u>Item</u>	<u>Description</u>	<u>Volume/Page</u>
	2. Date of Manufacture.....	5/1016
	3. Cold Storage Intervals.....	5/1016
	E. Sample Retention Program.....	5/1018
	F. Container-Closure Integrity.....	6/1019
	G. Figures.....	5/1021
	H. References.....	5/1103
11.	PRODUCT LABELING, LABEL CONTROL PROCEDURES AND PROVISIONS FOR PRODUCT SAMPLES.....	5/1104
	A. Draft Labeling.....	5/1104
	1. Container Labeling.....	5/1104
	2. Package Labeling.....	5/1104
	3. Package Insert.....	5/1105
	B. Label Control Procedures.....	5/1106
	1. Amgen.....	5/1106
	2. Parke-Davis (Contract Filler).....	5/1108
	C. Provision to FDA of Product Samples/Protocols.....	5/1109
	D. Figures.....	5/1110
12.	RECORDS.....	5/1140
	A. Maintenance of Production Records.....	5/1140
	B. Shipping Records and Recall Procedures.....	5/1142
	C. Batch Records.....	5/1145
13.	NON-CLINICAL PHARMACOLOGY.....	5/1146
	A. Equivalence of Amgen- and Kirin-Produced r-HuEPO.....	5/1146

05027136

Amgen Confidential Business Information,
Subject To ITC Protective Order

A 27117

AM 17 048941
CONFIDENTIAL
SUBJECT TO PROTECTIVE ORDER

r-HuEPO Product License Application
Table of Contents

Amgen, Inc.
1900 Oak Terrace Lane
Thousand Oaks, CA 91320

<u>Item</u>	<u>Description</u>	<u>Volume/Page</u>
B.	Preclinical Animal Efficacy and Pharmacokinetic Experiments.....	5/1147
C.	Detection of Antibodies to r-HuEPO in Animal Sera.....	5/1174
D.	Pharmacology Review.....	5/1199
E.	Non-Clinical Absorption, Distribution, Metabolism and Excretion (Intravenous Administration), Chronic Renal Failure.....	5/1212
F.	Toxicology Review.....	6/1228
	Individual study summaries.....	6/1252
14.	CLINICAL DATA.....	6/1297
A.	Integrated Summary of Efficacy.....	6/1298
B.	Integrated Summary of Safety.....	6/1320
C.	Listing of Clinical Investigations.....	6/1355
D.	Study Report, Phase I/II.....	6/1361
E.	Pharmacokinetics.....	10/2580
F.	Study Report, Phase III.....	10/2642
G.	Statistical Report.....	13/3461
15.	BIBLIOGRAPHY.....	14/4131
16.	ENVIRONMENTAL ASSESSMENT STATEMENT.....	14/4145
17.	STATEMENT OF GMP COMPLIANCE.....	14/4159
18.	NAMES AND TITLES OF EXPERTS.....	14/4160
19.	CERTIFICATION AND SIGNATURE OF RESPONSIBLE HEAD.....	14/4161

05027137

Amgen Confidential Business Information,
Subject To ITC Protective Order

AM 17 048942
CONFIDENTIAL
SUBJECT TO PROTECTIVE ORDER

A 27118

r-HuEPO Product License Application
Table of Contents

Amgen, Inc.
1900 Oak Terrace Lane
Thousand Oaks, CA 91320

APPENDICES

(Bound as Separate Volumes)

<u>Appendix</u>	<u>Type</u>	<u>Title</u>
2.C-1	Study Report	MWCB 51B Characterization Study Report
2.C-2	Cell Bank	Karyology Study of Candidate Cell Bank
6.C-1	License Application	Parke-Davis Establishment License Application
8.C-1	Product Testing	Contract Laboratories Performing Product Testing
12.D-1	Batch Records	Manufacturing Batch Records r-HuEPO Lot 516C7A
12.D-2	Batch Records	Manufacturing Batch Records r-HuEPO Lot 517E7
13.A-1	Safety Studies	Analysis of r-HuEPO Produced by Kirin Brewery Co., Ltd., Utilized for Animal Safety Studies
13.D-1	Study Report	General Pharmacological Study of KRN5702 (r-HuEPO)
13.E-1	Study Report	Metabolic Fate of ¹²⁵ I-KRN5702 (r-HuEPO) in Rats: I
13.F-1	Study Report	Acute Toxicity Study of KRN5702 (r-HuEPO) in Rats
13.F-2	Study Report	Acute Toxicity Study of KRN5702 (r-HuEPO) in Mice
13.F-3	Study Report	Acute Intravenous Toxicity Study of Recombinant Human Erythropoietin in the Rat
13.F-4	Study Report	Intravenous Acute Toxicity Study of KRN5702 (r-HuEPO) in Dogs

05027138

Amgen Confidential Business Information,
Subject To ITC Protective Order

A 27119

AM 17 048943
CONFIDENTIAL
SUBJECT TO PROTECTIVE ORDER

r-HuEPO Product License Application
Table of Contents

Amgen, Inc.
1900 Oak Terrace Lane
Thousand Oaks, CA 91320

<u>Appendix</u>	<u>Type</u>	<u>Title</u>
13.F-5	Study Report	A Four-Week Intravenous Subacute Toxicity Study of KRNS702 r-HuEPO in Rats with a Four-Week Recovery Period
13.F-6	Study Report	A 14-Day Subcutaneous Subacute Toxicity Study of Recombinant Human Erythropoietin in Albino Rats
13.F-7	Study Report	Thirteen-Week Intravenous Subacute Toxicity Study of KRNS702 (r-HuEPO) in Rats with a Five-Week Recovery Period
13.F-8	Study Report	A Four-Week Intravenous Subacute Toxicity Study of KRNS702 (r-HuEPO) in Dogs (A Preliminary Study for a Subacute Toxicity Study)
13.F-9	Study Report	A Four-Week Intravenous Subacute Toxicity Study of KRNS702 (r-HuEPO) in Dogs
13.F-10	Study Report	Intravenous Subacute Toxicity Study of Recombinant Human Erythropoietin in the Beagle Dog
13.F-11	Study Report	A Thirteen-Week Intravenous Subacute Toxicity Study of KRNS702 (r-HuEPO) in Dogs with a Five-Week Recovery Period
13.F-12	Study Report	Preliminary Teratology Study of KRNS702 (r-HuEPO) by Intravenous Administration in Rats
13.F-13	Study Report	Mutagenicity Testing of KRNS702 (r-HuEPO)
13.F-14	Study Report	Hematologic Study of Recombinant Human Erythropoietin Administered Intravenously to Beagle Dogs
13.F-15	Study Report	Antigenicity Study of KRNS702 (r-HuEPO)

05027139

Amgen Confidential Business Information,
Subject To ITC Protective Order

A 27120

AM 17 048944
CONFIDENTIAL
SUBJECT TO PROTECTIVE ORDER

r-HuEPO Product License Application
Table of Contents

Amgen, Inc.
1900 Oak Terrace Lane
Thousand Oaks, CA 91320

<u>Appendix</u>	<u>Type</u>	<u>Title</u>
13.F-16	Study Report	Study on the Pyrogenicity of KRN5702 (r-HuEPO) in Rabbits
13.F-17	Study Report	Effect of Erythropoietin (r-HuEPO) on Brain Sensitivity in Mice and Brain Water and Electrolyte Distribution in Rats
14.B-1	Listing	Adverse Events, Phase I/II Study (Through 4/30/87)
14.B-2	Listing	Adverse Events, Phase III Study (Through 4/30/87)
14.B-3	Listing	Adverse Events, Phase I/II and III (4/30/87 Through 8/31/87)
14.F-1	Phase III Site Report	University of Alabama
14.F-2	Phase III Site Report	University of Arizona
14.F-3	Phase III Site Report	University of California, Los Angeles
14.F-4	Phase III Site Report	Cleveland Clinic Foundation
14.F-5	Phase III Site Report	University of Missouri
14.F-6	Phase III Site Report	State University of New York Health Science Center at Brooklyn
14.F-7	Phase III Site Report	Rush-Presbyterian-St. Luke's Medical Center
14.F-8	Phase III Site Report	University of Washington
14.F-9	Phase III Site Report	Vanderbilt University
15.A-1	Literature Copies	Referenced Material

04/17/00

Amgen Confidential Business Information
Subject To ITC Protective Order

A 27121

AM 17 048945
CONFIDENTIAL
SUBJECT TO PROTECTIVE ORDER